Prokidney announces closing of purchase of manufacturing facility in greensboro, nc

Winston-salem, n.c., july 18, 2023 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (ckd), today announced it has closed on its purchase of a 210,000 square foot facility and approximately 22 acres of land in greensboro, n.c. prokidney paid approximately $25.5 million in cash for the facility and property. the company plans to make investments in the facility through 2028 to prepare for potential commercial-scale manufacturing of react®, its proprietary renal autologous cell therapy, currently in phase 3 development for the treatment of diabetic ckd.
PROK Ratings Summary
PROK Quant Ranking